Cipher Pharmaceuticals (CPH) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 2025 net revenue of $13.4 million, up 152% year-over-year, driven by strong U.S. NATROBA/Natroba™ business and growth in the Canadian product portfolio.

• NATROBA/Natroba™ revenues reached $7.8 million in Q2 and $14.4 million for the first half of 2025, up 16% sequentially from Q1 2025.

• Net income for Q2 2025 was $5.9 million ($0.22–$0.23 per diluted share), compared to $3 million ($0.12) in Q2 2024, mainly due to Natroba™ contribution.

• Strong cash generation with $6 million from operations; $15 million debt repaid and $2.1 million in share repurchases in Q2 2025.

• Subsequent $7 million debt repayment post-quarter, leaving $11.3 million cash and $47 million available credit.

Financial highlights

• Total net revenue for Q2 2025 was $13.4 million, up 152% year-over-year; six-month revenue was $25.4 million, up 127%.

• Adjusted EBITDA for Q2 2025 was $7.6 million, up 148% year-over-year; $13.8 million for the first half, up 108%.

• EBITDA for Q2 2025 was $8.6 million, up 290% year-over-year.

• Gross profit was $10.9 million, up 159% year-over-year; gross margin rose to 81%.

• Operating cash flow was $6 million in Q2 and $10.2 million for the first half of 2025.

Outlook and guidance

• Expect continued strong performance from NATROBA/Natroba™, especially entering the seasonally high-demand Q3.

• Ongoing efforts to expand NATROBA's Medicaid preferred status in additional U.S. states and to launch in Canada.

• Intends to out-license Natroba™ globally and acquire complementary dermatology products.